{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:21:14Z","timestamp":1759936874418,"version":"3.40.5"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T00:00:00Z","timestamp":1472428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ygyno.2016.08.331","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T03:41:14Z","timestamp":1473392474000},"page":"246-251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["A comparison of overall survival with 40 and 50 mg\/m 2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data"],"prefix":"10.1016","volume":"143","clinical-trial-number":[{"clinical-trial-number":"umin000003130","registry":"10.18810\/umin-japan"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5530-6873","authenticated-orcid":false,"given":"Masahiko","family":"Nakayama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisanori","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomihiro","family":"Takahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiko","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutake","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2016.08.331_bb0005","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2016.08.331_bb0010","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"24 Suppl 6","key":"10.1016\/j.ygyno.2016.08.331_bb0015","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0020","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0025","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0030","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0035","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1200\/JCO.2011.36.9215","article-title":"Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer","volume":"30","author":"Kaye","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0040","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","article-title":"Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer","volume":"30","author":"Colombo","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0045","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1006\/gyno.2000.5921","article-title":"Phase 2 trial of liposomal doxorubicin (40mg\/m(2)) in platinum\/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum","volume":"78","author":"Markman","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/gyno.2001.6272","article-title":"Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages","volume":"82","author":"Rose","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0055","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2009.04.007","article-title":"Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer","volume":"114","author":"Tanyi","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2004.09.046","article-title":"Role of pegylated liposomal doxorubicin in ovarian cancer","volume":"96","author":"Thigpen","year":"2005","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0065","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1200\/JCO.2007.13.6606","article-title":"Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer","volume":"26","author":"Ferrandina","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0070","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0075","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"von Moos","year":"2008","journal-title":"Eur. J. Cancer"},{"year":"2015","series-title":"Treatment Guidelines for Ovarian Cancer","author":"The Japan Society of Gynecologic Oncology","key":"10.1016\/j.ygyno.2016.08.331_bb0080"},{"key":"10.1016\/j.ygyno.2016.08.331_bb0085","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"year":"2015","series-title":"Propensity Score Analysis - Statistical Methods and Applications-","author":"Guo","key":"10.1016\/j.ygyno.2016.08.331_bb0090"},{"key":"10.1016\/j.ygyno.2016.08.331_bb0095","doi-asserted-by":"crossref","unstructured":"Tsolakidis D, Amant F, Leunen K et al. Comparison of diaphragmatic surgery at primary or interval debulking in advanced ovarian carcinoma: an analysis of 163 patients. Eur. J. Cancer 47: 191\u2013198.","DOI":"10.1016\/j.ejca.2010.08.020"},{"key":"10.1016\/j.ygyno.2016.08.331_bb0100","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1056\/NEJMsa020080","article-title":"Specialty of ambulatory care physicians and mortality among elderly patients after myocardial infarction","volume":"347","author":"Ayanian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0105","first-page":"192","article-title":"Safety evaluation of pegylated liposomal doxorubicin in 2144 patients with recurrent\/relapsed or refractory ovarian cancer, -the results of post-marketing surveillance in Japan-","volume":"33","author":"Kawabata","year":"2015","journal-title":"Jpn. J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0110","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1200\/JCO.1994.12.2.241","article-title":"Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer","volume":"12","author":"Schiller","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0120","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1200\/JCO.1995.13.10.2575","article-title":"Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer","volume":"13","author":"Seidman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0125","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/jjco\/hyn101","volume":"38","author":"Katsumata","year":"2008","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0130","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejon.2006.10.004","article-title":"Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre","volume":"11","author":"Webster-Gandy","year":"2007","journal-title":"Eur. J. Oncol. Nurs."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0135","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/NCC.0b013e3181a38fc3","article-title":"The experience of a sore mouth and associated symptoms in patients with cancer receiving outpatient chemotherapy","volume":"32","author":"Brown","year":"2009","journal-title":"Cancer Nurs."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0140","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2014.60.4587","article-title":"Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO quality of life working group","volume":"33","author":"Hofheinz","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0145","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1023\/A:1008240421028","article-title":"Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients","volume":"8","author":"Eisenhauer","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0150","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.critrevonc.2007.04.004","article-title":"Treatment of recurrent ovarian cancer relapsing 6\u201312months post platinum-based chemotherapy","volume":"64","author":"Colombo","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0155","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/jama.1992.03490130097037","article-title":"Hospital characteristics and quality of care","volume":"268","author":"Keeler","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.ygyno.2016.08.331_bb0160","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1097\/IGC.0000000000000213","article-title":"Effects of access to and treatment in specialist facilities on survival from epithelial ovarian cancer in Australian women: a data linkage study","volume":"24","author":"Tracey","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2016.08.331_bb0165","first-page":"363","article-title":"Twenty one multicentral studies on prognosis of advanced ovarian cancer; focused on correlation between primary surgical procedure following adjuvant chemotherapies and 4year survival rates","volume":"45","author":"Terashima","year":"1993","journal-title":"Nihon Sanka Fujinka Gakkai Zasshi"},{"key":"10.1016\/j.ygyno.2016.08.331_bb0170","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0175","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s13577-012-0057-0","article-title":"Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin","volume":"26","author":"Yokomichi","year":"2013","journal-title":"Hum. Cell"},{"key":"10.1016\/j.ygyno.2016.08.331_bb0180","doi-asserted-by":"crossref","first-page":"4735","DOI":"10.1002\/cncr.25262","article-title":"A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients","volume":"116","author":"von Gruenigen","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2016.08.331_bb0185","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.breast.2014.02.005","article-title":"Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92\/08)","volume":"23","author":"Templeton","year":"2014","journal-title":"Breast"},{"key":"10.1016\/j.ygyno.2016.08.331_bb0190","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000351801","article-title":"Efficient prevention strategy against the development of a palmar-plantar erythrodysesthesia during chemotherapy","volume":"27","author":"Lademann","year":"2014","journal-title":"Skin Pharmacol. Physiol."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0195","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0749-2081(03)00059-7","article-title":"Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer","volume":"19","author":"Edwards","year":"2003","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.ygyno.2016.08.331_bb0200","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ygyno.2014.01.036","article-title":"A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy","volume":"132","author":"Previs","year":"2014","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816313579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816313579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T21:45:09Z","timestamp":1601070309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816313579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S0090825816313579"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.08.331","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comparison of overall survival with 40 and 50mg\/m2 pegylated liposomal doxorubicin treatment in patients with recurrent epithelial ovarian cancer: Propensity score-matched analysis of real-world data","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.08.331","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}